- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studiendaten | - | Investing.com Deutsch | ||
| Di | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| Di | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| Mo | Zenas BioPharma presents extended obexelimab data for IgG4-RD | 3 | Investing.com | ||
| 07.10. | Zenas BioPharma to present MS research at Toronto conference | 2 | Investing.com | ||
| 07.10. | Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 | 1 | GlobeNewswire (USA) | ||
| 06.10. | Zenas BioPharma to Host Virtual R&D Event | 2 | GlobeNewswire (USA) | ||
| 30.09. | Zenas Biopharma: H.C. Wainwright bestätigt Kaufempfehlung vor PDUFA-Entscheidung | 2 | Investing.com Deutsch | ||
| 30.09. | H.C. Wainwright reiterates Zenas Biopharma stock rating ahead of PDUFA | 2 | Investing.com | ||
| 30.09. | Guggenheim reiterates Zenas Biopharma stock rating on IgG4-RD outlook | 1 | Investing.com | ||
| 30.09. | Guggenheim bestätigt Kaufempfehlung für Zenas Biopharma nach IgG4-RD-Update | - | Investing.com Deutsch | ||
| 23.09. | Can Zenas BioPharma's (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn? | 2 | Insider Monkey | ||
| 22.09. | Zenas BioPharma to present obexelimab IgG4-RD trial data | 20 | Investing.com | ||
| 18.09. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.09. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.09. | Zenas BioPharma auf Citi-Konferenz: Pipeline-Strategie und Finanzplanung vorgestellt | 3 | Investing.com Deutsch | ||
| 08.09. | Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event | 1 | GlobeNewswire (USA) | ||
| 18.08. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 13.08. | Zenas BioPharma GAAP EPS of -$1.77 misses by $0.65, revenue of $1M | 2 | Seeking Alpha | ||
| 13.08. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 387,75 | +0,16 % | Amgen springt nach Kursziel-News - was jetzt zählt | ||
| REGENERON PHARMACEUTICALS | 711,80 | +0,23 % | Regeneron - REGN: Pasatru mit anhaltender Wirkung bei FOP! | Besser als Placebo! Breakout-Setup bei Regeneron-Aktie (REGN) mit Kursziel 860 USD. Kommt der Rückenwind aus dem Healthcare-Sektor? Widerstand bei 785 USD! Regeneron (REGN) - US75886F1075 Rückblick... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,450 | 0,00 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity | SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
| TEMPUS AI | 63,67 | +0,39 % | Should You Buy, Hold or Sell Tempus AI Stock Amid AI Boom? | ||
| BIOMARIN PHARMACEUTICAL | 50,08 | +0,18 % | Raymond James upgrades BioMarin stock to strong buy on valuation | ||
| ARROWHEAD PHARMACEUTICALS | 51,90 | -0,54 % | Cantor Fitzgerald reiterates Arrowhead Pharma stock rating on trial data | ||
| INSMED | 88,95 | +0,52 % | Insmed launches four phase 3 trials for lung disease therapy | ||
| SWEDISH ORPHAN BIOVITRUM | 39,080 | -0,91 % | Sobi UK: NICE issues final draft guidance recommending - Tryngolza (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales | FOR UK HEALTHCARE/TRADE MEDIA ONLY
Sobi UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza (olezarsen)... ► Artikel lesen | |
| SCHOLAR ROCK | 38,340 | +5,85 % | Truist reiterates Buy on Scholar Rock stock, $77 target on launch | ||
| PROQR THERAPEUTICS | 1,321 | +1,77 % | ProQR Therapeutics N.V.: ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 | LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,579 | -3,16 % | Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA | ~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 79,92 | -0,02 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| TEVOGEN | 5,510 | -9,23 % | Tevogen Inc.: Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements | WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. ("Tevogen" or the "Company") (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and... ► Artikel lesen | |
| CG ONCOLOGY | 61,86 | 0,00 % | CG Oncology appoints Isabel Kalofonos as chief commercial officer | ||
| RECURSION PHARMACEUTICALS | 4,155 | -0,12 % | Recursion (RXRX) Enters New Growth Phase as Sanofi Kicks Off Drug Collab, Shares Soar |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 25,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.